In-vivo Thrombus Imaging With 18F-GP1, a Novel Platelet PET Radiotracer
In-vivo Thrombus Imaging With 18F-GP1, a Novel Platelet PET Radiotracer
To date, the investigators have successfully employed a radiotracer (18F-sodium fluoride) as a marker of necrotic inflammation in human atherosclerosis. The investigators aim to further the mechanistic understanding of atherothrombosis by studying the activation of glycoprotein IIb/IIIa receptors in cardiovascular thrombus using the novel platelet radiotracer (18F-GP1). Binding of 18F-GP1 to activated platelets in venous and arterial thrombi has already been demonstrated in pre-clinical studies and a phase 1 trial in man. If successful, this study would define the role of the glycoprotein IIb/IIIa receptor within in vivo thrombosis across a range of cardiovascular diseases.
Cardiovascular thrombotic conditions were estimated to account for 1 in 4 deaths worldwide in 2010 and are the leading cause of global mortality. Divided into arterial and venous thromboses, ischaemic heart disease and ischemic stroke comprise the major arterial thromboses and deep-vein thrombosis and pulmonary embolism comprise the major venous thromboses. Although both arterial and venous thrombi differ in both aetiology and pathophysiology, many commonalities remain.
Thrombosis begins with damage to the vascular wall. Physiological haemostasis is triggered when underlying collagen is exposed to circulating platelets which bind directly to collagen with collagen-specific glycoprotein surface receptors. After an initial signalling cascade involving release of platelet binder von Willebrand Factor, platelets become activated which allows adherence to the site of injury. Following activation, phospholipase A2 modifies the integrin membrane glycoprotein IIb/IIIa (GP IIb/IIIa) increasing platelet ability to bind fibrinogen. The activated platelets then change shape from spherical to stellate, and the fibrinogen cross-links with glycoprotein IIb/IIIa aiding aggregation of more platelets and completing primary haemostasis. Secondary haemostasis involves activation of the coagulation cascade through extrinsic and intrinsic pathways and ends with cross linked fibrin deposition and a mature thrombus.
The haemostatic process is fluid and dynamic with the expression of activated membrane proteins and coagulation factors changing throughout. Platelet expression of GP IIb/IIIa falls as a thrombus matures hence why it is a pharmacological target for antithrombotic therapies. The investigators aim to explore the expression and distribution of GP IIb/IIIa receptors in a range of thrombotic conditions listed below spanning across both arterial and venous systems. Improving understanding of how clinical presentation relates to platelet activation over a range of conditions is crucially important when deciding appropriate anti-thrombotic regimes.
1.2.1 Coronary Heart Disease and Myocardial Infarction Coronary heart disease is the leading cause of death worldwide and is responsible for 17.5 million or 46% of all non-communicable deaths in 2012. The majority of the cardiovascular morbidity and mortality is attributable to coronary atherosclerosis and thrombosis. Atherosclerosis is the central process by which the heart arteries narrow and harden due to the deposition of fatty plaques within the artery wall. This process can result in damage to the lining of the artery which can cause a thrombus (clot) to form within the artery which can partially or completely occlude the flow of blood to the heart muscle thereby precipitating myocardial infarction. This is the commonest form of a heart attack and responsible for a large proportion of sudden cardiac deaths. Thrombus in myocardial infarction is classically thought to be composed of predominantly platelets. However, recent research has shown that 56% of thrombus in MI is composed of fibrin with only 17% platelets. Ischaemic time correlated positively with thrombus fibrin content and negatively with thrombus platelet component. This illustrates the dynamic interaction between platelets and fibrin over time.
1.2.2 Bioprosthetic heart valve thrombosis Bioprosthetic valve thrombosis is an increasingly recognised complication of valve replacement. Patient risks include early prosthesis failure requiring redo operation plus stroke or other systemic embolism. A meta-analysis has estimated the incidence of bioprosthetic thrombosis to be 0.03 per 100 patient years with the risk of embolism being highest in the first 3 months post implantation. The composition of prosthetic valve thrombosis varies depending on valve type and time from insertion. Interestingly in the MISTRAL-C randomised controlled trial, 50% of acute thromboembolic events within 3 days of transcatheter aortic valve insertion were platelet-fibrin thrombus, not calcific debris from the aortic root. Thromboembolism was less common in those on anticoagulant rather than antithrombotic treatment suggesting a fibrin predominance. Similar results were found in a large registry of over 25,000 patients undergoing surgical bioprosthetic valve insertion. Warfarin plus aspirin was more effective than aspirin alone in preventing thromboembolic events and death.
1.2.3 Venous thromboembolic disease Pulmonary embolism is a common cardiovascular condition with a high morbidity and mortality. Embolisation of a venous thrombosis from the deep veins of the lower limbs or pelvis is the aetiology in more than 90% events. Thrombus formation is triggered by intravascular activation of coagulation and thrombin-mediated intraluminal fibrin deposition. Red blood cells (RBCs) are thought to be incorporated into venous thrombi via passive trapping in the growing fibrin network, culminating in the production of a RBC and fibrin rich venous thrombus. Treatment for both DVT and PE reduces mortality and secondary prophylaxis with anticoagulation is effective at preventing further events. The clinically most frequently applied imaging test for visualisation of suspected PE is CT pulmonary angiography (CTPA). For DVT, a range of imaging modalities can be used (US, CT or MR) with ultrasound the most common first line investigation.
1.2.4 Stroke and Transient Ischaemic Attack (TIA) Stroke and TIA are leading causes of preventable death and morbidity worldwide. Thrombus composition is thought to depend on source (cardiac chamber or head or neck artery) and time from event. Fibrin-dominant thrombus is likely to be more refractory to thrombolytic drugs as is the presence of chronic histopathologic features in clots such as endothelialisation and calcification. Diagnosis is based on clinical presentation followed by CT or MRI of the brain with US or MR assessment of carotid stenosis performed thereafter to ascertain future event risk.
1.2.5 COVID-19 The COVID-19 pandemic has resulted in major mortality and morbidity. Consistent clinical concerns have been raised in published literature, news outlets and social media regarding thromboembolic events affecting the microvasculature as well as large vessels. This has received widespread attention and led to the reported use of prophylactic or therapeutic anticoagulation regimes, or even fibrinolysis, outwith standard protocols and indications in the absence of firm evidence of clinical benefit, such is the concern. Given its sensitivity for detecting activated platelets, which our pilot data has suggested may be superior to other imaging modalities in some settings, 18F-GP1 PET-CT may offer a suitable method to examine the posited association between COVID-19 and thromboembolic disease.
1.3 Understanding Platelet Biology As platelet aggregation is a major component of both arterial and venous thrombi, the investigators propose to explore whether a radiolabelled ligand (18F-GP1) of the glycoprotein IIb/IIIa (GPIIb/IIIa) receptor can detect activated platelets on thrombus. GPIIb/IIIa receptors mediate platelet adherence and aggregation. They are expressed in greater numbers and assume a more ligand binding conformation on activation which binds protein ligands including von Willebrand factor and Fibrinogen. This allows for platelet bridging and aggregation. Accordingly, they represent an attractive target for acute thrombus imaging. We hope to identify activated platelets in the five groups presented above. Identification of activated platelets in all conditions will further enhance our understanding of the role of this receptor in both arterial and venous thrombosis and how anti-thrombotic therapy influences expression.
1.4 Glycoprotein IIb/IIIa inhibition Three intravenous platelet glycoprotein (GP) IIb/IIIa inhibitors have been studied extensively and are available for clinical use: abciximab, tirofiban, and eptifibatide. Abciximab is a monoclonal antibody directed against the receptor, while tirofiban and eptifibatide are high affinity non-antibody receptor inhibitors.
Antiplatelet therapy with intravenous GP IIb/IIIa inhibitors has been evaluated in patients with acute coronary syndrome (ACS) and in those undergoing intracoronary stent implantation and stroke but not DVT/PE or prosthetic valve implantation.
Meta-analyses have evaluated the use of intravenous glycoprotein (GP) IIb/IIIa inhibitors in a variety of settings related to coronary disease. The impact of the intravenous GP IIb/IIIa inhibitors on clinical outcomes was assessed in a pooled analysis of 21 trials involving various groups of patients with ischemic heart disease. The GP IIb/IIIa inhibitor reduced the combined end point of death, nonfatal myocardial infarction (MI), or urgent revascularization at 30 days in the following groups of patients:
In stroke disease, a single randomised controlled trial (SaTIS) performed in moderate ischaemic stroke demonstrated a significant reduction in mortality at 5 months with tirofiban when compared to placebo. Importantly there was no difference in major haemorrhage.The investigators aim to explore the expression of GPIIb/IIIa in stroke and TIA and explore how it may differ in the embolised thrombus when compared with the culprit plaque.
Efficacy of GPIIb/IIIa inhibition in recent bioprosthetic valve insertion and DVT/PE is unknown. We aim to explore activated platelet expression in both conditions to gain insight as to whether GPIIb/IIIa inhibition may be a potentially useful treatment.
1.5 Background of 18F-GP1 GP1 is a ligand of the fiban class of molecule which has a high affinity for the glycoprotein IIb/IIIa receptor; highly expressed on activated platelets. It is an excellent target for imaging arterial thrombi with a large activated platelet component. After a 2 step radiofluorination subsequent purification process 18F-GP1 can be used for PET imaging.
18F-GP1 has undergone pre-clinical and phase 1 clinical evaluation demonstrating a high affinity to GPIIb/IIIa, the key receptor for platelet aggregation. It binds in a stable and specific manner to in vivo arterial, venous and intracardiac human thrombus. Binding is crucially not altered by anticoagulation therapy (aspirin and heparin).
In the recent phase 1 study 18F-GP1 demonstrated a high detection rate of thromboembolic foci in 20 patients with recently formed deep vein thrombi (DVT) and pulmonary thromboemboli. The tracer also performed favourably with regards to its metabolism, pharmacokinetic and dosimetry profile. There were no significant adverse events in any of the 20 recruited participants.
1.6 Study Aims
We aim to examine the expression of the glycoprotein IIb/IIIa receptor in:
1.7 Research Hypothesis
GPIIb/IIIa receptor expression is varied by thrombotic condition including venous (DVT/PE) versus arterial (MI/stroke), in situ (MI) versus embolic (stroke, PE) and prosthetic material (stents and valves) versus diseased native tissue (MI, stroke, DVT/PE).
1.8 Rationale for Study To date, the investigators have successfully employed a radiotracer (18F-sodium fluoride) as a marker of necrotic inflammation in human atherosclerosis. Binding of 18F-GP1 to activated platelets in venous and arterial thrombi has already been demonstrated in pre-clinical studies and a phase 1 trial in man. If successful, this study would define the role of the glycoprotein IIb/IIIa receptor within in vivo thrombosis across a range of cardiovascular diseases.
4.2 Myocardial infarction group inclusion/exclusion criteria 4.2.1 Myocardial infarction Inclusion criteria
4.2.2 Myocardial infarction Exclusion Criteria Subjects should not enter the study if any of the following criteria are fulfilled
4.3 Stable CAD inclusion/exclusion criteria
4.3.1 Stable CAD inclusion criteria
4.3.2 Stable coronary disease exclusion criteria
4.4 Bioprosthetic heart valve inclusion/exclusion criteria
4.4.1 Bioprosthetic aortic valve inclusion criteria
4.4.2 Bioprosthetic heart valve exclusion criteria
4.5 DVT/PE inclusion/exclusion criteria 4.5.1 DVT/PE inclusion criteria
4.5.2 DVT/PE exclusion criteria
4.6 Stroke and TIA inclusion/exclusion criteria
4.6.1 Stroke and TIA inclusion criteria
4.6.2 Stroke and TIA exclusion criteria